Revium Rx. Reiterates Going Concern, Reports $1.5M Cash and Ineffective Controls
RVRC has more than doubled off its 52-week low of $0.3 on light trading volume (0.3× avg).
Summary
Revium Rx.'s Q2 2026 report shows only $1.5 million in cash, a reiterated going concern warning, and ineffective disclosure controls, while its lead drug program advances to Phase 1.
Key Events · Earnings and Guidance · RVRC
-
Going Concern Reiterated
Management states substantial doubt about the company's ability to continue as a going concern, with an accumulated deficit of $26.4 million and no binding commitments for additional capital.
-
Cash Runway Critical
Cash and short-term deposits total approximately $1.5 million as of June 30, 2026, down from $2.7 million at year-end 2025, with net cash used in operations of $1.2 million for the first half.
-
Ineffective Disclosure Controls
The CEO and CFO concluded that disclosure controls and procedures were not effective as of June 30, 2026, indicating ongoing internal control weaknesses.
-
Nano-Mupirocin Phase 1 Approval
The Israeli Ministry of Health granted approval to initiate Phase 1 clinical trials for Nano-Mupirocin in healthy volunteers, a key milestone for the lead program.
Analysis · RVRC · Life Sciences
The quarterly report confirms the company's precarious financial position: $1.5 million in cash against an accumulated deficit of $26.4 million, with no binding commitments for additional capital. Management again states substantial doubt about its ability to continue as a going concern. The disclosure controls and procedures are not effective, adding governance risk. On the operational side, the Nano-Mupirocin program received Israeli Ministry of Health approval to begin Phase 1 trials, a positive step, but the Nano-Candesartan program is stalled by a dispute with Yissum over a scientific report. The recent executive departures—CFO and COO—are also detailed, including a $45 thousand termination benefit and a $111 thousand option modification charge. For a company with a market cap around $101 million, the cash runway is extremely short, and the need for financing is urgent.
At the time of this filing, RVRC was trading at $1.67 on OTC in the Life Sciences sector, with a market capitalization of approximately $101.4M. The 52-week trading range was $0.30 to $50.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.